PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
Molecular identification and selection of probiotic strains able to reduce the serum TMAO level in mice challenged with choline
L-Carnite is a popular supplement because of its health and fitness benefits
Designed for gym-ready energy and clarity without compromising ingredient integrity or performance quality
Interactive effect of sulfur and nitrogen on nitrogen accumulation and harvest in oilseed crops differing in nitrogen assimilation potential
Combined with Lion's Mane's NGF-stimulating activity, this creates a synergistic approach: Lion's Mane stimulates NGF expression, while ALCAR provides the neuronal energy and acetylcholine precursor support required for neurons to utilise that NGF signal.* L-Glutamine (750mg per serving) Matching ALCAR in dose at 750mg
